DelveInsight’s “Postherpetic Neuralgia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Postherpetic Neuralgia, historical and forecasted epidemiology as well as the Postherpetic Neuralgia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Postherpetic Neuralgia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Postherpetic Neuralgia Market Forecast
Some of the key facts of the Postherpetic Neuralgia Market Report:
- The Postherpetic Neuralgia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- According to Sonnenreich and Dunkin (2021), 1 million Americans are thought to experience shingles each year. And while though the rash usually goes away in 2 to 4 weeks without any serious side effects, in around 20% of instances, nerve injury results in pstherpetic neuraglia (PNH)
- According to NHS UK (2021), about 1 in 5 shingles patients go on to acquire PHN, and those who are 50 or older are more likely to do so
- According to Gruver and Guthmiller (2022), PHN develops in 9–14.3% of patients one month following the onset of shingles, and in 5% of patients three months later. 3% of people still have significant pain after a year
- Key Postherpetic Neuralgia Companies: Confo Therapeutics, Lexicon Pharmaceuticals, KAI Pharmaceuticals, Grünenthal GmbH, Toray Industries, Pfizer, Winston Laboratories, Xenon Pharmaceuticals Inc., Bausch Health, Shanghai SIMR, Haisco Pharmaceutical, NeurAxon Inc., Teva Pharma, Convergence Pharma, Daewoong Pharma, Daiichi Sankyo, and others
- Key Postherpetic Neuralgia Therapies: CFTX-1554, LX9211, KAI-1678, Lidocaine, TRK-700, Pregabalin, Civamide Patch, XPF-002, Retigabine, SR419, HSK16149, NXN-462, TV-45070, CNV2197944, DWP05195, DS-5565, and others
- The Postherpetic Neuralgia epidemiology based on gender analyzed that Postherpetic Neuralgia (PHN) is more prominent in females in comparison to males
- The Postherpetic Neuralgia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Postherpetic Neuralgia pipeline products will significantly revolutionize the Postherpetic Neuralgia market dynamics.
Postherpetic Neuralgia Overview
A prevalent form of neuropathic pain condition known as postherpetic neuralgia (PHN) is pain that lasts at least 90 days after the start of a rash at the site of acute herpes zoster.
Get a Free sample for the Postherpetic Neuralgia Market Report
https://www.delveinsight.com/report-store/postherpetic-neuralgia-market
Postherpetic Neuralgia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Postherpetic Neuralgia Epidemiology Segmentation:
The Postherpetic Neuralgia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Postherpetic Neuralgia
- Prevalent Cases of Postherpetic Neuralgia by severity
- Gender-specific Prevalence of Postherpetic Neuralgia
- Diagnosed Cases of Episodic and Chronic Postherpetic Neuralgia
Download the report to understand which factors are driving Postherpetic Neuralgia epidemiology trends @ Postherpetic Neuralgia Epidemiology Forecast
Postherpetic Neuralgia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Postherpetic Neuralgia market or expected to get launched during the study period. The analysis covers Postherpetic Neuralgia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Postherpetic Neuralgia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Postherpetic Neuralgia Therapies and Key Companies
- CFTX-1554: Confo Therapeutics
- LX9211: Lexicon Pharmaceuticals
- KAI-1678: KAI Pharmaceuticals
- Lidocaine: Grünenthal GmbH
- TRK-700: Toray Industries
- Pregabalin: Pfizer
- Civamide Patch: Winston Laboratories
- XPF-002: Xenon Pharmaceuticals Inc.
- Retigabine: Bausch Health
- SR419: Shanghai SIMR
- HSK16149: Haisco Pharmaceutical
- NXN-462: NeurAxon Inc.
- TV-45070: Teva Pharma
- CNV2197944: Convergence Pharma
- DWP05195: Daewoong Pharma
- DS-5565: Daiichi Sankyo
Discover more about therapies set to grab major Postherpetic Neuralgia market share @ Postherpetic Neuralgia Treatment Market
Postherpetic Neuralgia Market Strengths
- Its Incidence rate is significantly high, especially among geriatric population
Postherpetic Neuralgia Market Opportunities
- Absence of approved targeted therapies presents companies with a considerable first mover’s advantage in the PHN treatment market
Scope of the Postherpetic Neuralgia Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Postherpetic Neuralgia Companies: Confo Therapeutics, Lexicon Pharmaceuticals, KAI Pharmaceuticals, Grünenthal GmbH, Toray Industries, Pfizer, Winston Laboratories, Xenon Pharmaceuticals Inc., Bausch Health, Shanghai SIMR, Haisco Pharmaceutical, NeurAxon Inc., Teva Pharma, Convergence Pharma, Daewoong Pharma, Daiichi Sankyo, and others
- Key Postherpetic Neuralgia Therapies: CFTX-1554, LX9211, KAI-1678, Lidocaine, TRK-700, Pregabalin, Civamide Patch, XPF-002, Retigabine, SR419, HSK16149, NXN-462, TV-45070, CNV2197944, DWP05195, DS-5565, and others
- Postherpetic Neuralgia Therapeutic Assessment: Postherpetic Neuralgia current marketed and Postherpetic Neuralgia emerging therapies
- Postherpetic Neuralgia Market Dynamics: Postherpetic Neuralgia market drivers and Postherpetic Neuralgia market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Postherpetic Neuralgia Unmet Needs, KOL’s views, Analyst’s views, Postherpetic Neuralgia Market Access and Reimbursement
To know more about Postherpetic Neuralgia companies working in the treatment market, visit @ Postherpetic Neuralgia Clinical Trials and Therapeutic Assessment
Table of Contents
1. Postherpetic Neuralgia Market Report Introduction
2. Executive Summary for Postherpetic Neuralgia
3. SWOT analysis of Postherpetic Neuralgia
4. Postherpetic Neuralgia Patient Share (%) Overview at a Glance
5. Postherpetic Neuralgia Market Overview at a Glance
6. Postherpetic Neuralgia Disease Background and Overview
7. Postherpetic Neuralgia Epidemiology and Patient Population
8. Country-Specific Patient Population of Postherpetic Neuralgia
9. Postherpetic Neuralgia Current Treatment and Medical Practices
10. Postherpetic Neuralgia Unmet Needs
11. Postherpetic Neuralgia Emerging Therapies
12. Postherpetic Neuralgia Market Outlook
13. Country-Wise Postherpetic Neuralgia Market Analysis (2019–2032)
14. Postherpetic Neuralgia Market Access and Reimbursement of Therapies
15. Postherpetic Neuralgia Market Drivers
16. Postherpetic Neuralgia Market Barriers
17. Postherpetic Neuralgia Appendix
18. Postherpetic Neuralgia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
